Company / Net Income
ROCKET PHARMACEUTICALS, INC. Net Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$258.7M
FY2025
5-year range
-$258.7M / -$77.3M
FY2021-FY2025
Trend
-16.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has declined for 5 consecutive years, from -$75M in FY2020 to -$259M in FY2025.
Based on SEC 10-K filings.
-$259M in FY2025.
Declined from -$169M to -$259M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- ROCKET PHARMACEUTICALS, INC.'s net income has declined for 5 consecutive years.
- In FY2025, net income decreased 16.6% year-over-year.
- Peak net income was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.68 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$258.7M | -16.6% |
| FY2024 | -$221.9M | -31.2% |
| FY2023 | -$169.1M | -21.0% |
| FY2022 | -$139.7M | -80.8% |
| FY2021 | -$77.3M | -3.7% |
| FY2020 | -$74.5M | +0.0% |
| FY2019 | -$74.5M | -884.0% |
| FY2018 | -$7.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026